Dorit Ben-Shachar

List of Publications by Year
in descending order

68 papers	4,437 citations	109321 35 h-index	114465 63 g-index
68 all docs	68 docs citations	68 times ranked	4640 citing authors

#	Article	IF	Citations
1	Update of Mitochondrial Network Analysis by Imaging: Proof of Technique in Schizophrenia. Methods in Molecular Biology, 2021, 2277, 187-201.	0.9	2
2	NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia. Molecular Psychiatry, 2020, 25, 805-820.	7.9	22
3	Heme metabolism, mitochondria, and complex I in neuropsychiatric disorders. , 2020, , 173-207.		1
4	The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinsonâ€™s disease and in schizophrenia. Journal of Neural Transmission, 2020, 127, 159-168.	2.8	15
5	Mitochondrial function parameters as a tool for tailored drug treatment of an individual with psychosis: a proof of concept study. Scientific Reports, 2020, 10, 12258.	3.3	9
6	Impaired heme metabolism in schizophrenia-derived cell lines and in a rat model of the disorder: Possible involvement of mitochondrial complex I. European Neuropsychopharmacology, 2019, 29, 577-589.	0.7	6
7	Isolated Mitochondria Transfer Improves Neuronal Differentiation of Schizophrenia-Derived Induced Pluripotent Stem Cells and Rescues Deficits in a Rat Model of the Disorder. Schizophrenia Bulletin, 2018, 44, 432-442.	4.3	81
8	Mitochondrial Targeted Therapies: Where Do We Stand in Mental Disorders?. Biological Psychiatry, 2018, 83, 770-779.	1.3	16
9	Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes â€“ A Tool to Study Neurodevelopmental Disorders as ADHD. Frontiers in Cellular Neuroscience, 2018, 12, 321.	3.7	22
10	Gene expression dynamics following mithramycin treatment: A possible model for postâ€chemotherapy cognitive impairment. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1028-1037.	1.9	4
11	Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target. Schizophrenia Research, 2017, 187, 3-10.	2.0	76
12	Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia. Canadian Journal of Psychiatry, 2016, 61, 457-469.	1.9	132
13	Gene environment interaction in periphery and brain converge to modulate behavioral outcomes: Insights from the SP1 transient early in life interference rat model. World Journal of Psychiatry, 2016, 6, 294.	2.7	1
14	The role of branched chain amino acid and tryptophan metabolism in ratâ€™s behavioral diversity: Intertwined peripheral and brain effects. European Neuropsychopharmacology, 2015, 25, 1695-1705.	0.7	11
15	Analysis of Mitochondrial Network by Imaging: Proof of Technique in Schizophrenia. Methods in Molecular Biology, 2015, 1265, 425-439.	0.9	2
16	Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. International Journal of Neuropsychopharmacology, 2014, 17, 337-340.	2.1	6
17	Designer Aminoglycosides That Selectively Inhibit Cytoplasmic Rather than Mitochondrial Ribosomes Show Decreased Ototoxicity. Journal of Biological Chemistry, 2014, 289, 2318-2330.	3.4	97
18	Dexamethasone in the presence of desipramine enhances MAPK/ERK1/2 signaling possibly via its interference with Î²-arrestin. Journal of Neural Transmission, 2014, 121, 289-298.	2.8	10

#	Article	IF	Citations
19	Î²-endorphin degradation and the individual reactivity to traumatic stress. European Neuropsychopharmacology, 2013, 23, 1779-1788.	0.7	11
20	Early postnatal interference with the expression of multiple Sp1 regulated genes leads to disparate behavioral response to sub-chronic and chronic stress in rats. Psychoneuroendocrinology, 2013, 38, 2173-2183.	2.7	5
21	Platelets: A possible glance into brain biological processes in schizophrenia. World Journal of Psychiatry, 2012, 2, 124.	2.7	41
22	Differential expression of genes encoding neuronal ion-channel subunits in major depression, bipolar disorder and schizophrenia: implications for pathophysiology. International Journal of Neuropsychopharmacology, 2012, 15, 869-882.	2.1	37
23	Perturbation in Mitochondrial Network Dynamics and in Complex I Dependent Cellular Respiration in Schizophrenia. Biological Psychiatry, 2011, 69, 980-988.	1.3	120
24	Dexamethasone enhances the norepinephrine-induced ERK/MAPK intracellular pathway possibly via dysregulation of the Î±2-adrenergic receptor: Implications for antidepressant drug mechanism of action. European Journal of Cell Biology, 2010, 89, 712-722.	3.6	27
25	Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1318-1328.	1.7	16
26	DNA methylation in vulnerability to post-traumatic stress in rats: evidence for the role of the post-synaptic density protein Dlgap2. International Journal of Neuropsychopharmacology, 2010, 13, 347.	2.1	65
27	Mitochondrial complex I as a novel target for intraneuronal DA: Modulation of respiration in intact cells. Biochemical Pharmacology, 2009, 78, 85-95.	4.4	49
28	The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. Journal of Neural Transmission, 2009, 116, 1383-1396.	2.8	39
29	Mitochondrial Complex I Subunits are Altered in Rats with Neonatal Ventral Hippocampal Damage but not in Rats Exposed to Oxygen Restriction at Neonatal Age. Journal of Molecular Neuroscience, 2009, 38, 143-151.	2.3	14
30	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	2.6	64
31	Physical stress differs from psychosocial stress in the pattern and time-course of behavioral responses, serum corticosterone and expression of plasticity-related genes in the rat. Stress, 2009, 12, 412-425.	1.8	52
32	Mitochondrial Complex I as a Possible Novel Peripheral Biomarker for Schizophrenia. , 2009, , 71-83.		2
33	Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: Relevance to dopamine pathology in schizophrenia. Biochimica Et Biophysica Acta - Bioenergetics, 2008, 1777, 173-185.	1.0	69
34	Norepinephrineâ€"glucocorticoids interaction does not annul the opposite effects of the individual treatments on cellular plasticity in neuroblastoma cells. European Journal of Pharmacology, 2008, 596, 14-24.	3.5	16
35	Neuroanatomical Pattern of Mitochondrial Complex I Pathology Varies between Schizophrenia, Bipolar Disorder and Major Depression. PLoS ONE, 2008, 3, e3676.	2.5	164
36	Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 807-813.	4.8	59

#	Article	IF	Citations
37	Major depression as a disorder of serotonin resistance: inference from diabetes mellitus type II. International Journal of Neuropsychopharmacology, 2007, 10, 839-50.	2.1	6
38	Sp1 Expression Is Disrupted in Schizophrenia; A Possible Mechanism for the Abnormal Expression of Mitochondrial Complex I Genes, NDUFV1 and NDUFV2. PLoS ONE, 2007, 2, e817.	2.5	72
39	Increased mRNA levels of the mitochondrial complex I 75-kDa subunit. European Child and Adolescent Psychiatry, 2006, 15, 504-507.	4.7	32
40	Alterations in cell adhesion molecule L1 and functionally related genes in major depression: A postmortem study. Biological Psychiatry, 2005, 57, 716-725.	1.3	50
41	Mitochondria, Synaptic Plasticity, And Schizophrenia. International Review of Neurobiology, 2004, 59, 273-296.	2.0	160
42	Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotoxicity Research, 2003, 5, 35-43.	2.7	103
43	Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochemical Pharmacology, 2003, 66, 489-494.	4.4	189
44	Modulation of frequency and duration of repetitive magnetic stimulation affects catecholamine levels and tyrosine hydroxylase activity in human neuroblastoma cells: implication for the antidepressant effect of rTMS. International Journal of Neuropsychopharmacology, 2003, 6, 233-241.	2.1	32
45	Norepinephrine alters the expression of genes involved in neuronal sprouting and differentiation: relevance for major depression and antidepressant mechanisms. Journal of Neurochemistry, 2002, 83, 1054-1064.	3.9	63
46	Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. Journal of Neurochemistry, 2002, 83, 1241-1251.	3.9	199
47	The effects of bile acids on Î²-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochemical Pharmacology, 2000, 59, 1623-1628.	4.4	41
48	Paroxetine binding in aggressive schizophrenic patients. Psychiatry Research, 2000, 94, 77-81.	3.3	17
49	Neuromelanin may Mediate Neurotoxicity via its Interaction with Redox Active Iron. , 2000, , 211-218.		4
50	Therapeutic Efficacy of Right Prefrontal Slow Repetitive Transcranial Magnetic Stimulation in Major Depression. Archives of General Psychiatry, 1999, 56, 315.	12.3	487
51	Chronic repetitive transcranial magnetic stimulation alters Î²-adrenergic and 5-HT2 receptor characteristics in rat brain. Brain Research, 1999, 816, 78-83.	2.2	129
52	Increased mitochondrial complex I activity in platelets of schizophrenic patients. International Journal of Neuropsychopharmacology, 1999, 2, 245-253.	2.1	92
53	Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration. Journal of Neurochemistry, 1995, 64, 718-723.	3.9	257
54	Typical and Atypical Neuroleptics Induce Alteration in Bloodâ€Brain Barrier and Brain ⁵⁹FeCl₃ Uptake. Journal of Neurochemistry, 1994, 62, 1112-1118.	3.9	35

#	Article	IF	Citations
55	Iron and Parkinsonâ€™s Disease. , 1994, , 63-78.		1
56	Iron, melanin and dopamine interaction: relevance to parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, IN3-150.	4.8	43
57	Ironâ€Melanin Complex in Substantia Nigra of Parkinsonian Brains: An Xâ€Ray Microanalysis. Journal of Neurochemistry, 1992, 59, 1168-1171.	3.9	304
58	Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment. European Journal of Pharmacology, 1991, 202, 177-183.	3.5	15
59	Iron-Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease. Journal of Neurochemistry, 1991, 57, 1609-1614.	3.9	294
60	Neuroleptic-Induced Supersensitivity and Brain Iron: I. Iron Deficiency and Neuroleptic-Induced Dopamine D2Receptor Supersensitivity. Journal of Neurochemistry, 1990, 54, 1136-1141.	3.9	25
61	Selective Alteration in Blood-Brain Barrier and Insulin Transport in Iron-Deficient Rats. Journal of Neurochemistry, 1988, 50, 1434-1437.	3.9	43
62	Enhancing effects of fluoride-containing ceramic implants on bone formation in the dog femur. Journal of Cranio-Maxillo-Facial Surgery, 1988, 16, 40-45.	1.7	5
63	Characterization of the hepatic prolactin receptors induced by chronic iron deficiency and neuroleptics. European Journal of Pharmacology, 1986, 122, 259-267.	3.5	10
64	Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. International Journal of Developmental Neuroscience, 1986, 4, 81-88.	1.6	105
65	Brain Iron and Dopamine D2 Receptors in the Rat. Advances in Behavioral Biology, 1986, , 263-269.	0.2	0
66	Effect of Iron Chelators on Dopamine D2Receptors. Journal of Neurochemistry, 1985, 45, 999-1005.	3.9	85
67	Increased hepatic and reduced prostatic prolactin (PRL) binding in iron deficiency and during neuroleptic treatment: Correlation with changes in serum PRL and testosterone. European Journal of Pharmacology, 1985, 109, 193-200.	3.5	36
68	Nutritional iron and dopamine binding sites in the rat brain. Pharmacology Biochemistry and Behavior, 1982, 17, 43-47.	2.9	140